Impact of the Oral Microbiota on Relapse in HNSCC Patients
Phase 4
Active, not recruiting
- Conditions
- Head and Neck Cancer
- Registration Number
- NCT06807034
- Lead Sponsor
- Institut Sainte Catherine
- Brief Summary
to characterise the impact of microbiota in radiotherapy efficacy
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- head and neck cancer
Exclusion Criteria
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Microbiota 2 years Analysis of buccal microbiota by 16SrRNA gene sequencing
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does oral microbiota composition modulate radiotherapy efficacy via PI3K/AKT/mTOR pathways in HNSCC relapse?
What comparative effectiveness data exist for microbiota-targeted radiotherapy versus cetuximab in HNSCC recurrence prevention?
Which 16S rRNA-derived biomarkers predict response to radiotherapy in HPV-positive HNSCC patients per NCT06807034?
How does dysbiosis of oral microbiota correlate with radiotherapy-induced mucositis and xerostomia in HNSCC patients?
What combination strategies with microbiota modulation enhance HNSCC radiotherapy outcomes compared to standard-of-care regimens?
Trial Locations
- Locations (1)
ICAP
🇫🇷Avignon, France